Product Details
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
Description
The Raji/Human PD-L1 Stable Cell Line was engineered to express the full length human PD-L1 (Uniprot: Q9NZQ7-1), used to mimic cancer target cells. When co-cultured with human PD-1 Reporter Cell, the PD-1/PD-L1 interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the PD-1/PD-L1 interaction by either anti-PD-1 or anti-PD-L1 antibodies releases the inhibitory signal and results in TCR activation and NFAT-mediated luminescence.
Application
• Useful for cell-based PD-L1 binding assay
• Useful as PD-L1-expressing target cells in reporter gene assay

Growth Properties
Suspension
Selection Marker
Puromycin (2 μg/mL)
Complete Growth Medium
RPMI-1640 + 10% FBS
Freeze Medium
Serum-free cell cryopreservation medium
Quantity
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
Storage
Frozen in liquid nitrogen.
Mycoplasma Testing
Negative
Sterility Testing
Negative
Instructions for Use
See data sheet for detailed culturing and assay protocol.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Receptor Assay

Expression analysis of human PD-L1 on Raji/Human PD-L1 Stable Cell by FACS.
Raji/Human PD-L1 Stable Cell Line or negative control cell were stained with PE-labeled anti-human PD-L1 antibody.Protocol
Application

Blocking activity of anti-human PD-1 antibody (RLU).
This Raji/Human PD-L1 Stable Cell Line was incubated with serial dilutions of antibodies in the presence of reporter cells expressing human PD-1. The EC50 of anti-human PD-1 antibody was approximately 1.189 μg/mL.Protocol
Blocking activity of anti-human PD-1 antibody (FOLD).
This Raji/Human PD-L1 Stable Cell Line was incubated with serial dilutions of antibodies in the presence of reporter cells expressing human PD-1. The max induction fold was approximately 22.47.Protocol
Passage Stability

Passage stability analysis of receptors expression by FACS.
Flow cytometry surface staining of human PD-L1 on Raji/Human PD-L1 Stable Cell Line demonstrates consistent mean fluorescent intensity across passage 13-29.Protocol
Customer Reviews Writing Reviews

Important Statement
Limited Use&License Disclosure
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
- If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
- Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
- This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
Recent Advances
- English Name:
Programmed death-ligand 1
- Category:
- Approved Drugs:
12 Details
- Drugs in Clinical Trials:
176 Details
- Highest Development Stage:
Approved




















